Probi AB (publ) (PBBIF)
Probi AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SE. The stock last traded at $24.00, up 0.00% on the session, giving a market capitalisation of $286.9M. On trailing twelve-month figures it carries a trailing P/E of 160.00, a net margin of 2.7%. Its beta of 0.44 implies it has historically moved less than the broad market.
Probi AB (publ) is a Swedish entity specializing in the discovery, development, production, marketing, and distribution of probiotic solutions, which it supplies to clients across the health, pharmaceutical, and food sectors. The company conducts extensive research, with a primary focus on gut health, digestive well-being, immune system function, bone density, and efficient iron absorption, as well as addressing specific health needs for children, women, and the elderly. Its diverse product range includes both dietary supplements and various food and beverage items. These are available in numerous formats, such as capsules, tablets (including chewable and spherical types), powders, and an assortment of liquid options like fruit drinks, shots, carbonated beverages, and recovery drinks. Probi's market presence spans approximately 40 countries worldwide. The firm engages in significant academic collaborations, notably partnering with Örebro University for research into innovative needle-free vaccines and with La Trobe University to conduct a clinical trial examining the impact of Probi Osteo on Australian women. Founded in 1991 and headquartered in Lund, Sweden, Probi AB (publ) operates as a subsidiary of Symrise AG.
Probi AB (publ) is most often compared with the following Healthcare names: